Literature DB >> 24835348

Protective effect of chitosan treatment against acetaminophen-induced hepatotoxicity.

Eda Ozcelik1, Sema Uslu2, Nilufer Erkasap3, Hadi Karimi2.   

Abstract

Acetaminophen (APAP) is the most commonly reported toxic ingestion in the world. Severe liver injury resulting from overdose or chronic use of APAP remains a significant clinical problem. In recent years, the mechanisms underlying liver injury caused by APAP have become much better understood. We have studied the protective effect of chitosan supplementation against APAP-induced hepatotoxicity with respect to changes in the levels of total and lipid-bound sialic acid in the serum and in the liver tissue and changes in the activity of diagnostic marker enzymes, lipid peroxidation, and ceruloplasmin oxidase enzyme in normal and experimental groups of rats. During the experimental period, chitosan (200 mg/kg body weight per day) was administered to APAP + chitosan-treated rats by oral gavage. Results showed that treatment with APAP induced a significant increase in the serum alanine aminotransferase and alkaline phosphatase activities, in total and lipid-bound sialic acids levels, and in the liver lipid peroxide content. The administration of chitosan significantly prevented APAP-induced alterations in the levels of diagnostic marker enzymes, total sialic acid, lipid-bound sialic acid, and malondialdehyde in the experimental groups of rats. Furthermore, chitosan administration increased the activity of ceruloplasmin oxidase. In conclusion, our results suggest that chitosan has a protective effect on APAP-induced hepatic injury in rats. The study sheds light on the therapeutic potential of chitosan in an APAP-induced hepatotoxicity model.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Acetaminophen; Chitosan; Hepatotoxicity; Sialic acid

Mesh:

Substances:

Year:  2014        PMID: 24835348     DOI: 10.1016/j.kjms.2014.02.003

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  7 in total

1.  The Use of Chitosan-Coated Nanovesicles in Repairing Alcohol-Induced Damage of Liver Cells in Mice.

Authors:  Loredana Nicoleta Hilițanu; Liliana Mititelu-Tarțău; Maria Bogdan; Beatrice Rozalina Buca; Ana-Maria Raluca Păuna; Liliana Lăcrămioara Pavel; Ana-Maria Pelin; Andreea-Daniela Meca; Grațiela Eliza Popa
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

2.  Gold Nanoparticles Perturb Drug-Metabolizing Enzymes and Antioxidants in the Livers of Male Rats: Potential Impact on Drug Interactions.

Authors:  Mohammed Y I Al-Hamadani; Abdullah M Alzahrani; Mokhtar I Yousef; Maher A Kamel; Wael M El-Sayed
Journal:  Int J Nanomedicine       Date:  2020-07-14

Review 3.  Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review.

Authors:  Mirjana Stanić Benić; Lana Nežić; Vesna Vujić-Aleksić; Liliana Mititelu-Tartau
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

4.  Morin encapsulated chitosan nanoparticles (MCNPs) ameliorate arsenic induced liver damage through improvement of the antioxidant system and prevention of apoptosis and inflammation in mice.

Authors:  Sanchaita Mondal; Sujata Das; Pradip Kumar Mahapatra; Krishna Das Saha
Journal:  Nanoscale Adv       Date:  2022-05-17

5.  Effect of betulinic acid administration on TLR-9/NF-κB /IL-18 levels in experimental liver injury

Authors:  Eda Dokumacioğlu; Hatice Iskender; Kübra Asena Terim Kapakin; Güler Yenice; Behzat Mokthare; İsmail Bolat; Armağan Hayırlı
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

6.  Therapeutic effect of chitosan on CCl4‑induced hepatic fibrosis in rats.

Authors:  Zhong-Feng Wang; Mao-Yu Wang; De-Hai Yu; Yan Zhao; Hong-Mei Xu; Sheng Zhong; Wen-Yi Sun; Yu-Fang He; Jun-Qi Niu; Pu-Jun Gao; Hai-Jun Li
Journal:  Mol Med Rep       Date:  2018-08-01       Impact factor: 2.952

Review 7.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.